I've written a few times about open data in the context of clinical trials - the information that must be provided when new drugs seek approval. As I noted, there is a growing movement to make such basic safety data freely available, the idea being that it could then be analysed by third parties, perhaps finding new applications of drugs, overlooked problems, or even wilful concealing of adverse effects.
On Open Enterprise blog.
No comments:
Post a Comment